Lipids & metabolic liver disease
Statin Use and Development and Progression of Nonalcoholic Fatty Liver Disease Based on Ultrasonography
Authors' conclusion
Taking statin may decrease the risk of NAFLD occurrence and progression in the population with statin indication, suggesting the potential role of statin both in primary and secondary prevention strategies for NAFLD, especially among those with low or moderate ASCVD risk.
Study context
- Population
- Participants aged 18 years with statin indication, enrolled 2010–2017, Kailuan Study and Kailuan General Hospital electronic medical records21,229 non-NAFLD, 22,419 nonalcoholic fatty liver disease (NAFLD)
- Exposure
- Statin users vs nonstatin users
- Outcome
- NAFLD occurrence, progression and regression
- Follow-up
- Median about 4 years
Methodological detailspropensity-score matched cohorts also used
- Propensity-score matched cohorts also used
Main finding
As reported in the abstract
Statin users
84.7/1000 person-years
Nonstatin users
106.5/1000 person-years
Statin users vs Nonstatin usersHazard ratio (95% CI)
NAFLD occurrence
0.78(0.70–0.87)
NAFLD regression (as printed)
0.71(0.60–0.84)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Cumulative statin duration ≥2 yearsStatin usersvs Nonstatin usersOccurrence | 0.56 (0.46–0.69) | |
| Cumulative statin duration ≥2 yearsStatin usersvs Nonstatin usersProgression | 0.52 (0.30–0.90) | |
| Low or moderate ASCVD riskStatin usersvs Nonstatin usersOccurrence | 0.74 (0.66–0.82) | |
| Low or moderate ASCVD riskStatin usersvs Nonstatin usersProgression | 0.68 (0.57–0.80) | |
| 0.20.5125Hazard ratio (log scale) |
Propensity score (PS)-matched cohort
- The PS-matched cohort had similar results
Original publication
Statin Use and Development and Progression of Nonalcoholic Fatty Liver Disease Based on Ultrasonography. J Clin Endocrinol Metab. Published 16 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →